QLT (QLTI) Said The FDA To Review Aczone labeling supplement
More News related to QLTI
- QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
- QLT announces positive results from the evaluation of Visudyne(R) combination therapy
- Massachusetts Court Dismisses All Claims Filed by MGH Against QLT Inc. (QLTI) Except Those Under Chapter 93A
- QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
- QLT (QLTI) Swings to Q1 Profit
More News related to FDA
- CombinatoRx (CRXX) Publishes Research Demonstrating Improved Selectivity Through Synergistic Combinations
- Spectrum Pharmac (SPPI) Receives Complete Response Letter from FDA for Zevalin
- Lilly (LLY) Receives Fourth FDA Approval for ALIMTA
- Protalix (PLX) Approached by the FDA to Consider Submitting a Treatment Protocol for the Use of prGCD
- ATS Medical (ATSI) Announces FDA Clearance of New ATS Simulus Semi-Rigid Annuloplasty Band
QLT Inc. (NASDAQ: QLTI) said the FDA has accepted for filing and review QLT USA, Inc.'s labeling supplement for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label. A decision by the FDA on the label revision is expected by the end of March 2008.
Related Categories
FDAStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
